Form 4: 10x Genomics Director Receives RSU Grant

Director Kimberly J. Popovits was granted 8,829 restricted stock units as part of her compensation package with 10x Genomics.

Summary

• Director Kimberly J. Popovits acquired 8,829 restricted stock units (RSUs) of 10x Genomics, Inc. Class A Common Stock.
• The transaction occurred on June 4, 2026.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs vest in quarterly installments over one year, beginning May 21, 2026, contingent upon continued service.
• Following this transaction, the director's total beneficial ownership is 37,445 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the director continuing as a service provider to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology and life sciences sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The use of quarterly vesting schedules for director RSUs is consistent with standard equity compensation practices for mid-to-large cap life sciences companies.
• The grant size is typical for board-level compensation in the genomics instrumentation industry.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• Quarterly vesting of the granted RSUs.

Key Dates

Keywords

10x Genomics, TXG, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction